Skip to main content
. 2022 Mar 2;2022(3):CD002795. doi: 10.1002/14651858.CD002795.pub3

Comparison 14. SARIs versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
14.1 Drop‐out rate due to treatment emergent adverse effects 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
14.1.1 Dropout rate 1 42 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.70, 1.09]
14.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms 1   Mean Difference (IV, Random, 95% CI) Subtotals only
14.2.1 CAPS: Total score 1 41 Mean Difference (IV, Random, 95% CI) ‐5.60 [‐21.26, 10.06]
14.2.2 CAPS subscale: Re‐experiencing/intrusion 1 41 Mean Difference (IV, Random, 95% CI) ‐1.30 [‐6.80, 4.20]
14.2.3 CAPS subscale: Avoidance/numbing 1 41 Mean Difference (IV, Random, 95% CI) ‐1.60 [‐9.23, 6.03]
14.2.4 CAPS subscale: Hyperarousal 1 41 Mean Difference (IV, Random, 95% CI) ‐2.90 [‐8.40, 2.60]
14.3 Drop‐out rate due to any cause 2   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
14.3.1 Dropout rate 2 101 Risk Ratio (M‐H, Random, 95% CI) 0.81 [0.68, 0.97]